Jeet Mahal
Directeur des opérations chez JASPER THERAPEUTICS, INC.
Fortune : 567 704 $ au 30/06/2024
Profil
Jeet Mahal is currently the Chief Operating Officer at Jasper Therapeutics, Inc. Prior to this, he held positions at Scios, Inc. as the Director of Business & New Product Development, Johnson & Johnson as the Director of Business & New Product Development, COR Therapeutics, Inc. as a Principal, and Portola Pharmaceuticals LLC as the Vice President of Strategic Marketing.
Mr. Mahal has an MBA from Duke University, a graduate degree from the Illinois Institute of Technology and North Carolina State University, an undergraduate degree from the University of California, Berkeley, and another MBA from The Fuqua School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/06/2024 | 25 009 ( 0,17% ) | 567 704 $ | 30/06/2024 |
Postes actifs de Jeet Mahal
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Directeur des opérations | 21/03/2022 |
Anciens postes connus de Jeet Mahal
| Sociétés | Poste | Fin |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2019 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/09/2008 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - |
Formation de Jeet Mahal
| University of California, Berkeley | Undergraduate Degree |
| Illinois Institute of Technology | Graduate Degree |
| North Carolina State University | Graduate Degree |
| The Fuqua School of Business | Masters Business Admin |
| Duke University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| JOHNSON & JOHNSON | Health Technology |
| Entreprise privées | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
